Verzenio® Tablets for HR+/HER2– Metastatic Breast Cancer

What Verzenio® Is and How It Works

Verzenio (abemaciclib) is an oral cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. It is used for hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced or metastatic breast cancer. Many shoppers compare Verzenio price and monthly cost when planning long-term treatment.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba, and prescriptions are reviewed by licensed pharmacists before dispensing.

We also partner with licensed, vetted international pharmacies to supply authentic brand medications, offering a broad selection at affordable prices.

By blocking CDK4/6, abemaciclib slows cancer cell cycle progression from G1 to S phase. Verzenio is taken by mouth as tablets. It may be prescribed:

– with an aromatase inhibitor as initial endocrine-based therapy

– with fulvestrant after disease progression on endocrine therapy

– as monotherapy after prior endocrine therapy and chemotherapy in the metastatic setting

Continuous dosing is a key feature of abemaciclib. Unlike some CDK4/6 inhibitors, Verzenio is given every day without a week off, following the prescriber’s plan.

Dosage and Usage

• Standard adult dosing with endocrine therapy: 150 mg by mouth twice daily.
• Monotherapy dosing: 200 mg by mouth twice daily.
• Available strengths: 50 mg, 100 mg, 150 mg, and 200 mg tablets. Prescribers reduce doses in 50 mg steps for safety or drug interactions.
• Take doses about 12 hours apart, at the same times each day.
• Take with or without food. Avoid grapefruit or grapefruit juice.
• Swallow tablets whole. Do not crush, chew, or split.
• If a dose is missed or vomited, skip it and take the next dose at the usual time. Do not take extra tablets.
• Follow lab monitoring for blood counts and liver enzymes as directed by the care team.
• Strong CYP3A inhibitors (for example, ketoconazole, clarithromycin) may require a reduced dose. Strong CYP3A inducers (for example, rifampin, carbamazepine) can lower exposure.

• Store Verzenio tablets at 20–25°C (68–77°F). Short excursions 15–30°C (59–86°F) are allowed.
• Keep in the original, tightly closed container. Protect from moisture.
• Keep out of reach of children and pets.
• For travel, carry your medication with you in hand luggage. Avoid leaving it in a parked car or direct heat.
• Bring enough tablets and a copy of your prescription for the entire trip.

Benefits and Savings

In HR+/HER2– metastatic breast cancer, Verzenio with endocrine therapy improves progression-free survival versus endocrine therapy alone. Continuous dosing can be convenient for those who prefer a steady schedule rather than a 3-weeks-on/1-week-off cycle.

Ordering Verzenio tablets from YouDrugstore gives access to Canadian pricing. Many customers see 60–80% savings versus typical US prices, which can lower the cost of Verzenio per month. Multi-month supplies and occasional bulk promotions may reduce per-month costs further. You can set simple reorder reminders in your account.

Current offers appear on our verzenio coupon page.

Side Effects and Safety

• Common side effects: diarrhea, nausea, vomiting, decreased appetite, abdominal pain, fatigue, headache.
• Hematologic effects: neutropenia, anemia, leukopenia, thrombocytopenia.
• Infections (including upper respiratory infections) may occur.
• Liver-related changes: increased ALT/AST, bilirubin.
• Other: hair thinning, mouth sores, weight loss, dizziness.

Serious risks include severe diarrhea with dehydration, febrile neutropenia or serious infection, interstitial lung disease/pneumonitis, hepatotoxicity, and venous thromboembolism (deep vein thrombosis or pulmonary embolism). Treatment is not recommended during pregnancy. Effective contraception is advised during therapy and for at least 3 weeks after the last dose. Do not breastfeed during treatment and for at least 3 weeks after the final dose.

Onset Time

Diarrhea often appears early, frequently within the first week, and is usually most pronounced during the initial cycles. Blood count changes typically emerge within the first 2 months, so early lab monitoring is standard. Radiographic assessment of response is commonly performed every 8–12 weeks in practice.

Clinical benefit can include delayed disease progression and symptom control when used with appropriate endocrine therapy. The time course varies by patient, prior treatments, metastatic sites, and the overall care plan.

Compare With Alternatives

Palbociclib (Ibrance) is another CDK4/6 inhibitor used with endocrine therapy. It uses a 21-days-on/7-days-off cycle. Neutropenia is frequent, and diarrhea tends to be less common than with abemaciclib. Some patients prefer continuous daily dosing with Verzenio; others tolerate palbociclib well on its cyclic schedule.

Ribociclib (Kisqali) is also combined with endocrine therapy on a 3-weeks-on/1-week-off cycle. Ribociclib requires monitoring for QT prolongation and liver enzyme elevations. Choice among CDK4/6 inhibitors often depends on medical history, monitoring needs, drug interactions, and side-effect profiles.

Therapies for other cancers, such as Bavencio® or Zytiga®, are available from YouDrugstore but are not alternatives for HR+/HER2– breast cancer. Your oncology team selects the class and regimen suited to the diagnosis.

Combination Therapy

• With aromatase inhibitors (for example, letrozole, anastrozole) as first-line endocrine-based therapy.
• With fulvestrant after progression on prior endocrine therapy.
• With ovarian function suppression in premenopausal patients receiving endocrine therapy.
• With bone-targeted agents (for example, denosumab or bisphosphonates) when indicated for skeletal metastases.
• Consider dose modifications when strong CYP3A inhibitors are required or if adverse reactions occur.

Patient Suitability and Cost-Saving Tips

Verzenio is indicated for adults with HR+/HER2– advanced or metastatic breast cancer, either newly diagnosed in the advanced setting or after progression on endocrine therapy. It can be used with aromatase inhibitors or fulvestrant, or as monotherapy after certain prior treatments.

It may not suit those with uncontrolled infections, severe or persistent diarrhea, or significant baseline neutropenia. Dose adjustments are common for low blood counts, liver enzyme elevations, or drug interactions. Strong CYP3A inducers can reduce abemaciclib exposure and are usually avoided. Strong CYP3A inhibitors may require a lower tablet strength such as 100 mg.

Pregnancy and breastfeeding are not recommended during treatment. Contraception is advised during therapy and for 3 weeks after the last dose.

To manage the price of Verzenio and keep the abemaciclib tablet price predictable month to month, consider these tips:

• Choose a 2– or 3‑month supply when permitted; multi‑pack orders often lower the per‑month cost.
• Turn on reorder reminders in your account to avoid last‑minute purchases.
• Review promotions on our site when comparing the cost of Verzenio per month.
• Pricing at YouDrugstore reflects Canadian pricing; verzenio cost with insurance in the US varies by plan and typically does not apply to cross‑border pharmacy orders.

Authoritative Sources

For detailed prescribing information, consult these resources:

Eli Lilly Verzenio (abemaciclib) US Prescribing Information

FDA Label and Medication Guide for Abemaciclib

Health Canada Drug Product Database: Abemaciclib

Order Verzenio® from YouDrugstore: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This content is educational and does not replace personalized medical advice from a qualified professional. Always follow your oncology team’s directions.